Suvorexant Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 5 mg, 10 mg, 15 mg, 20 mg
Reference Brands: Belsomra (USA)
Category:
Sleep Disorders
Suvorexant is an orexin receptor antagonist used for the treatment of insomnia, helping patients fall asleep and stay asleep. It works by blocking the activity of orexin A and B, neurotransmitters responsible for promoting wakefulness, thereby supporting natural sleep.
Suvorexant is available in Tablets
and strengths such as 5 mg, 10 mg, 15 mg, 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Suvorexant is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Suvorexant can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Insomnia is a common sleep disorder characterized by difficulty falling asleep, trouble maintaining sleep throughout the night, or experiencing nonrestorative sleep that leaves individuals feeling tired even after adequate time in bed. These symptoms can vary from person to person and may occur occasionally or persist over a longer period, affecting daily functioning and overall well-being. Insomnia is one of the most frequently reported medical complaints in general practice and affects a significant portion of the adult population worldwide.
The condition can have a substantial impact on physical and mental health. Persistent sleep disturbances are associated with reduced concentration, fatigue, mood changes, and decreased productivity during the day. In addition, insomnia is considered a risk factor for several health concerns, including anxiety disorders, substance misuse, and major depression. If left unmanaged, it can significantly lower an individual’s quality of life. Proper evaluation, lifestyle modifications, improved sleep hygiene, and appropriate medical treatment can help manage insomnia effectively and improve sleep quality and overall health outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing